Enroll in an IgA nephropathy (IgAN) Clinical Trial

IgA nephropathy (IgAN), also known as Berger's disease, is a kidney disease that impacts roughly 60,000 people in the United States. IgAN occurs when an antibody called immunoglobulin A (IgA) builds up in the kidney and causes inflammation, which can hamper the kidneys' ability to filter waste from the blood over time.

Researchers are currently studying an investigational oral drug for IgAN and are seeking clinical trial volunteers. Participants must be over the age of 18 and have had a kidney biopsy that confirms their IgAN diagnosis. If you’re interested, answer a few questions below to check your eligibility.

Check eligibility

Study details

Phase
III
Number of participants
50 in the US
Duration
24-27 months
Is a placebo being used?
Yes
Sponsored by:
Novartis
Will the results of this trial be published?
Yes
Costs
You will not have to pay for any study treatment(s) or any study-related tests while you are in the study. However, the Sponsor will not pay for the costs of the usual care you need to maintain your health.

If you would like to speak to someone regarding this trial, first check to see if you are initially eligible through the prescreener above. If it seems that you are eligible to take part, you will be contacted by phone so we can ask you additional questions to confirm your eligibility, and you will be able to ask any questions you may have about this clinical trial. If you are not eligible based on your responses to the prescreener, you can always contact us at patientsupport@antidote.me to discuss further.

Click here to share this trial.